Comparison of ctDNA profiles from HR+/HER2-low and HR+/HER2-0 advanced breast cancer patients

被引：0
|
作者：
Dobric, N. [1 ]
Dandachi, N. [1 ]
Klocker, E. V. [1 ]
Suppan, C. [1 ]
Graf, R. [2 ]
Hasenleithner, S. [2 ]
Jost, P. J. [1 ]
Heitzer, E. [2 ]
Balic, M. [1 ]
机构：
[1] Med Univ Graz, Div Oncol, Dept Internal Med, Graz, Austria
[2] Med Univ Graz, Inst Human Genet, Graz, Austria
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.667
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
491P
引用
收藏
页码：S387 / S387
页数：1
相关论文
共 50 条
  • [1] Ribociclib in HR+/HER2-Advanced or Metastatic Breast Cancer Patients
    Rascon, Kaitlin
    Flajc, Goran
    De Angelis, Carmine
    Liu, Xinli
    Trivedi, Meghana V.
    Ekinci, Ekim
    ANNALS OF PHARMACOTHERAPY, 2019, 53 (05) : 501 - 509
  • [2] Abemaciclib for the treatment of HR+/HER2- breast cancer
    Exman, Pedro
    Tolaney, Sara M.
    EXPERT REVIEW OF PRECISION MEDICINE AND DRUG DEVELOPMENT, 2018, 3 (03): : 151 - 161
  • [3] Ribociclib effective in HR+, HER2– breast cancer
    Sidaway P.
    Nature Reviews Clinical Oncology, 2018, 15 (9) : 532 - 532
  • [4] HER2+/HR+ Breast Carcinoma Advanced Adjuvant with Neratinib
    Bischoff, Angelika
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (04) : 180 - 180
  • [5] Lapatinib plus letrozole for postmenopausal patients with advanced HER2+/HR+ breast cancer
    Guarneri, Valentina
    EXPERT REVIEW OF ANTICANCER THERAPY, 2009, 9 (11) : 1549 - 1557
  • [6] Preferences of Canadian Patients and Physicians for Treatment of HR+/HER2-Advanced Breast Cancer
    Stellato, Daniel
    Thabane, Marroon
    Eichten, Caitlin
    Delea, Thomas E.
    CURRENT ONCOLOGY, 2021, 28 (01) : 491 - 508
  • [7] Risks and benefits from CDK inhibitors for advanced HR+ Her 2-breast cancer
    Messina, C.
    Messina, M.
    Zanardi, E.
    ANNALS OF ONCOLOGY, 2017, 28 (12) : 3099 - 3100
  • [8] Abemaciclib for pre/perimenopausal women with HR+, HER2-advanced breast cancer
    Neven, Patrick
    Rugo, Hope S.
    Tolaney, Sara M.
    Iwata, Hiroji
    Toi, Masakazu
    Goetz, Matthew P.
    Kaufman, Peter A.
    Barriga, Susana
    Lin, Yong
    Sledge, George W.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [9] SG Improves OS in HR+/HER2-Breast Cancer
    Poh, Alissa
    CANCER DISCOVERY, 2022, 12 (12) : 2714 - 2715
  • [10] T-DXd Boosts PFS vs Chemo in HR+, HER2-Low Metastatic Breast Cancer
    不详
    ONCOLOGY-NEW YORK, 2024, 38 (07):
12345